where did the "buying power go" the last 6-8 weeks? Same place it went for the rest of stocks, particularly Nasdaq and particularly anything perceived as bio, into cash and out of stocks.
I might be wrong but I do not think they have the injectable included in their guidance for the year. I expect revs for 2014 closer to 120M
how_bout_we_talk, take a look at ICPT and its market cap, with no approved product merely a speculative value based on uncompleted trials
Correct.OSIR's PRODUCT revenues in Q4 were $8 million, MDXG were $18 million. I believe the divide between the two will expand throughout 2014. It's tough to sell your product when you have not one MAC in the country that has approved Grafix for reimbursement as opposed to MDXG having every one of them approved. Bubble brain and his other Sybils don't quite grasp that concept. But, they will learn, the hard way.
ozark, you are simply a morn and what's worse, a moron that can't even read and grasp simple financial terms. Do you understand what 5 times over subscribed means? it doesn't mean that a company issued more stock than it offered, it means that for every share they offered in their secondary, there was a demand for 5 times more nitwit. It means if they were selling 5 million shares as an example, they were contacted by institutions who if you added up their request, their was demand for 25 million shares. They still sold only 5 million nitwit. And, like most retail investors, you do not understand what the term "dilution means". Issuing stock is not necessarily dilutive at all the shareholders. Ever see a PR from a company acquiring another company in a stock deal where it says "the acquisition will be immediately accretive to earnings'. Is that dilution to shareholders? No, it is dilutive to S/h when stock is issued and EPS declines as a result,. When the cash raised is used to grow the business and EPS rises as a result, it was not dilutive.
We should. Up to 29% inst ownership as of 12/31, a lot more than previously including a lot of new ones including MFS
ozark. let me explain something once again to your feeble retail mind. Investors do not look at one time gains from sale of businesses. Do you really think any investor, other than a feeble retail investor like you, considers the one time $47 million gain as relevant to the ongoing business? it's about operating earnings, not one time liquidation gains. Income from operations pretax was a loss for OSIR for 2013 per the 10K
Much of it from the recent secondary which was 5X oversubscribed by institutions. Let me explain that to your feeble retail mind ozark. That means MDXG had to turn away a slew of institutions because the demand for stock was 5 times larger than what MDXG was offering to sell. Understand?
hey Ozark, learn how to read financial statements. MDXG has $44 million cash in the bank and was cash flow positive in in the quarter last reported. They are all set for cash. Looks like OSIR still in burn mode from operations
Yes we know why OSIR's CEO stepped down.."for personal reasons". Having been in management at public companies for 25 years, = asked to leave. Same as "to pursue other opportunities".
market maniac, as Lake Street pointed out last week "We would also note recent market entrants to the amniotic tissue space Osiris and Derma Sciences have yet to gain reimbursement from the Medicare Administrative Contractors (MACs) who actually pay out Medicare reimbursement on a regional basis. Given the aforementioned items, the question is not whether MiMedx will gain market share in 2014, the question is how much. Customers who were strongly incentivized to switch in 2014 will be less inclined to switch again in 2015 once EpiFix and the new reimbursement are entrenched/"
You see market mania, you can't sell and product when insurance isn't covering your product. That is why Epifix will dominate the space by year end and Grafix will be an after thought, besides the fact that Epifix is just better. Get it?
Market maniac, have you used both products like docsurick? I didn't think so. Now, get back to your Xbox
Your opinion holds about as much value on stocks as the guy that cuts my law and shovels my side drive and sidewalks. Epifix is eating Grafix's lunch.
I don't think its pure short selling earth but a combination of the big sell off particularly in Naz and particularly in bio (though MDXH not exactly bio I think it gets lumped in) but I am sure some shorts are taking advantage of the carnage to short also
$12-$15. Smelly, did you see doc asked about Q2 in 2015 not the current quarter? if those 2 positive outcomes happen, I see now way the stock is anywhere close to $6 a year from now